DOCSLIB.ORG

Centered You’Ll Explore Today’S Most Pressing Topics and Exciting New on Developments with Leaders from Around the Globe in Gastroenterology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Centered You’Ll Explore Today’S Most Pressing Topics and Exciting New on Developments with Leaders from Around the Globe in Gastroenterology mdedge.com/gihepnews February 2021 Volume 15 / Number 2 COVID-19 vaccines: INSIDE FROM THE AGA Are they safe for JOURNALS Pruritus in cholangiopathies immunocompromised Bezafibrate seems able AROLINA to help with “worst itch C possible.” • 6 ORTH patients? N OF BY ROXANNE NELSON, dose administration of the RN, BSN NIVERSITY /U MDedge News vaccine has been pegged Lessons in feeding at 95.0%, and the FDA has tubes TRICKLAND S - said that the 95% credible Training might not have RIAN covered it all. • 12 B Cality,oronavirus as they vaccines are interval for the vaccine Dr. Anne F. Peery, of University of North Carolina, Chapel Hill, have become a re clinicalefficacy trials,was 90.3%-97.6%. whether for recommends against surgery in certain patients. authorized for use in a But as with many initial GI ONCOLOGY growingnow being number approved of coun- and populations were repre- CRC in younger adults AGA Clinical Practice Update tries including the United senteddrugs or in vaccines, the trial cohort,not all Rates may be lower in adults under 50 than previously reported. • 15 Medical management of issuedStates. emergencyThe U.S. Food autho- and including individuals who rizationDrug Administration for the use of has the isare largely immunocompromised. unknown how ENDOSCOPY - As of December 2020, it- DOACs in elective colonic diverticulitis cine may be in this large procedures COVID-19 vaccine pro population,safe or effective many the of vacwhom It looks like they’re as BY AMY KARON duced by Pfizer and Bio- are at high risk for serious safe as vitamin K MDedge News NTech. Close behind was antagonists. • 22 diverticular stricture or - the vaccine developed of a two- by See Vaccines · page 19 new clinical practice toryfistula, bowel ischemic disease, colitis, Moderna. COVID-19 complications. update from the constipation, and, inflammaof the Uni- AGAThe efficacy Clinical Practice Update A - Anne F. Peery, MD, MSCR American Gastro - wroteversity in of North Carolina, How diet and exercise can help terologistsenterological with Association practical Chapel“In our Hill, practice, and associates patients seeks to provide gastroen are reassuredGastroenterology. to know that manage NAFLD for management of colonic ongoing symptoms are com- and evidence-based advice mon and often attributable BY AMY KARON tients with nonalcoholic - For example, clinicians MDedge News - shoulddiverticulitis. consider lower en- - FLD), according to a clin- progression,”fat, which provides wrote aZobair poten tionto visceral is particularly hypersensitivity,” import- xercise and a hypo- icalfatty practice liver disease update (NA from tial for reversal of disease they wrote. “This conversa Ecaloric, Mediterra- - - doscopy and CT scans of If needed, ongoing abdomi- nean-style diet remain M. Younossi, MD, MPH, of contrastthe abdomen to rule and out pelvis chronic nalant painafter cana negative be treated workup. with the“[W]eight American loss Gastroenter is associat- Inova Fairfax Medical Cam with oral and intravenous See Diverticulitis · page 5 - ological Association. pusSee in FallsDiet, Church, exercise Va., · page 6 first-line interventions with his associates. diverticular inflammation, that can benefit all pa ed with a reduction in liver At Digestive Disease Week® (DDW) 2021, now a fully virtual event, Centered you’ll explore today’s most pressing topics and exciting new on developments with leaders from around the globe in gastroenterology, Collaboration hepatology, endoscopy and gastrointestinal surgery. Rosemont, IL 60018 IL Rosemont, Suite 280 Suite 10255 W Higgins Road, Higgins W 10255 REGISTER ONLINE AT WWW.DDW.ORG/REGISTRATION. PERMIT 500 PERMIT CHANGE SERVICE REQUESTED SERVICE CHANGE HARRISBURG PA HARRISBURG PAID U.S. POSTAGE U.S. GI & Hepatology News Hepatology & GI PRSRT STD PRSRT May 21-23, 2021 | VIRTUAL 01_4 thru 9_19_20_GIHEP21_2.indd 1 1/22/2021 4:20:06 PM NEWS LETTER FROM THE EDITOR Finding common purpose, or else am composing this editorial 4 days after (Am J Gastroenterol. 2020 Jun;115[6]:916-23), the U.S. Capitol was invaded and 10 days among others, emphasized that mild GI symp- EWS Ibefore the presidential inauguration. It is toms may be the only presenting complaint for N impossible to ignore what is happening in our people with COVID-19. Responses to COVID-19, EDGE country, but I hesitate to add my thoughts to such as limits on elective procedures and social MD the overwhelming sea of opinions circulating distancing, have upended our endoscopic pro- in standard media, social media, and the dark cesses and even altered the business models of that infant mortality among African American web. I hope, as do many, that we return to a GI practice. We will never go back to pre-COVID women is 2.3 times that of non-Hispanic Whites models. (https://minorityhealth.hhs.gov/omh/browse. I hope, as do many, The front page of this month’s GI & Hepatol- aspx?lvl=4&lvlid=23). Late effects of redlining that we return to ogy News features important articles for our continue to cause economic, health, and emo- practice. One article delves into an extensive tional harms (Badger E. “How Redlining’s Rac- a civil discourse, guideline from the American Gastroenterological ist Effects Lasted for Decades.” The New York recognize the Association on medical management of colonic Times. 2017 Aug 24). diverticulitis. In another article, they also de- “If Men were angels, no government would be voices of all scribe how efforts to encourage our patients necessary,” James Madison wrote. “In framing a people, respect with nonalcoholic fatty liver disease to exercise government which is to be administered by men each other, and and manage their diet can make a real difference in their health. Finally, another explores how return to a belief in and why your immunocompromised patients governed;over men, theand great the next difficulty place, liesoblige in this:it to youcontrol science and facts. - itself.”must first enable the government to control the Dr. Allen ease) should and can be safely vaccinated for John I. Allen, MD, MBA, AGAF COVID-19(including .those with inflammatory bowel dis Editor in Chief civil discourse, recognize the voices of all peo- Meanwhile, we need civility, science, and com- ple, respect each other, and return to a belief in munity. Without common purpose, we will expe- science and facts. rience the William Forster Lloyd’s Tragedy of the Correction SARS-CoV-2 has devastated the world and Commons. Incivility has economic and emotional will continue to cause preventable deaths until costs, according to the Harvard Business Review The perspective for “Bariatric surgery re- we adopt stricter mitigation measures, vac- (Porath C and Pearson C. “The Price of Incivility.” solved NASH long term” that ran on pages cinate most people, and develop widespread 2013 Feb). “Weathering,” the deterioration of 4-5 of the October 2020 issue should read immunity. We are gaining immense knowledge Black women’s health over time that’s related “Cirrhosis regressed to F3 in two out of about this virus, and as gastroenterologists, we to continued socioeconomic disadvantage, has three patients” instead of “in two-thirds are on the front lines in many aspects. A recent multigenerational impacts; for example the De- of patients.” article in American Journal of Gastroenterology partment of Health & Human Services reports mdedge.com/gihepnews EDITOR IN CHIEF, GI & HEPATOLOGY NEWS GI & HEPATOLOGY NEWS is the official newspaper of the American FRONTLINE MEDICAL COMMUNICATIONS John I. Allen, MD, MBA, AGAF Gastroenterological Association (AGA) Institute and provides the gastroenterologist SOCIETY PARTNERS EDITOR IN CHIEF, THE NEW GASTROENTEROLOGIST with timely and relevant news and commentary about clinical developments Executive Editor Kathy Scarbeck, MA Vijaya L. Rao, MD and about the impact of health care policy. Content for GI & HEPATOLOGY NEWS Editor Christopher Palmer ASSOCIATE EDITORS is developed through a partnership of the newspaper’s medical board of editors Megan A. Adams, MD, JD, MSc (Editor in Chief and Associate Editors), Frontline Medical Communications Inc. Creative Director Louise A. Koenig Ziad Gellad, MD, MPH, AGAF and the AGA Institute Staff. “News from the AGA” is provided exclusively by the Director, Production/Manufacturing Kim L. Isaacs, MD, PhD, AGAF AGA, AGA Institute, and AGA Research Foundation. All content is reviewed by the Rebecca Slebodnik Charles J. Kahi, MD, MS, AGAF medical board of editors for accuracy, timeliness, and pertinence. To add clarity and National Account Manager Joshua Norton Gyanprakash A. Ketwaroo, MD, MSc context to important developments in the field, select content is reviewed by and 512-375-8202, [email protected] Larry R. Kosinski, MD, MBA, AGAF commented on by external experts selected by the board of editors. Sonia S. Kupfer, MD Senior Director of Classified Sales Tim LaPella, The ideas and opinions expressed in GI & HEPATOLOGY NEWS do not necessarily Wajahat Mehal, MD, PhD 484-921-5001, [email protected] reflect those of the AGA Institute or the Publisher. The AGA Institute and Frontline EDITORS EMERITUS, GI & HEPATOLOGY NEWS Medical Communications Inc. will not assume responsibility for damages, loss, Advertising Offices 7 Century Drive, Suite 302, Colin W. Howden, MD, AGAF or claims of any kind arising from or related to the information contained in Parsippany, NJ 07054-4609 973-206-3434 Charles J. Lightdale, MD, AGAF this publication, including any claims related to the products, drugs, or services Editorial Offices 2275 Research Blvd, Suite 400, EDITOR EMERITUS, THE NEW GASTROENTEROLOGIST mentioned herein. Advertisements do not constitute endorsement of products on Rockville, MD 20850, 240-221-2400 Bryson Katona, MD, PhD the part of the AGA Institute or Frontline Medical Communications Inc. AGA INSTITUTE STAFF POSTMASTER Send changes of address (with old mailing label) to GI & Managing Editor, GI & HEPATOLOGY NEWS, Jillian L. Schweitzer Hepatology News, Subscription Service, 10255 W Higgins Road, Suite 280, FRONTLINE Managing Editor, THE NEW GASTROENTEROLOGIST, Ryan A.
Load more

Recommended publications
  • Resource #350932
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2019 ~ Resource #350932 Anticipated Availability of First-Time Generics ―To help explain the benefits of generic drugs to your patients, the FDA has patient education materials available at https://www.fda.gov/drugs/generic-drugs/patient-education ― Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Acanya Benzoyl peroxide 2.5%/ Teva Generic now available (Valeant) Clindamycin phosphate 1.2% Cuprimine Penicillamine capsule Amerigen, Teva Generic now available (Bausch Health) Delzicol Mesalamine delayed-release Teva Generic now available (Warner Chilcott) capsule Diclegis Doxylamine/Pyridoxine Teva Generic now available (Duchesnay) Exjade Deferasirox tablets for oral Teva Generic now available (Novartis) suspension Fareston Toremifene Rising (EirGen Pharma Limited) Generic now available (Kyowa Kirin) Faslodex Fulvestrant Sandoz Generic now available (AstraZeneca) Firazyr Icatibant Teva Generic now available (Shire Orphan Therapies) Gablofen Baclofen 1 mg/mL single dose Mylan Institutional Generic now available (Piramal) vial Hemabate Carboprost tromethamine Dr. Reddy’s Generic now available (Pharmacia & Upjohn) Letairis Ambrisentan Cipla, Mylan, Par, Sigmapharm, Sun, Teva, Generic now available (Gilead) Zydus Lexiva Fosamprenavir Mylan Generic now available (Viv) More. Copyright © 2019 by Therapeutic Research Center 3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 pharmacist.therapeuticresearch.com ~ prescriber.therapeuticresearch.com ~ pharmacytech.therapeuticresearch.com ~ nursesletter.therapeuticresearch.com (Clinical Resource #350932: Page 2 of 24) Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Lotemax Loteprednol ophthalmic Hi-tech Generic now available (Bausch & Lomb) suspension Lyrica Pregabalin capsule Alembic, Amneal, Ascend (Alkem), Cipla Generic now available (PF Prism CV) (InvaGen), Dr.
    [Show full text]
  • Gilead Sciences, Inc. November 13, 2016
    Student Investment Management Gilead Sciences, Inc. November 13, 2016 Gilead Sciences, Inc. NASDAQ: GILD BUY $92.00 The Fisher College of Business Student Investment Management Program is initiating coverage on Gilead Sciences with a BUY rating. Our target price is $92.00. Our implied P/E for 2016E is 7.9x versus consensus 6.5x. Our 2017 and 2018 estimates are 8.8x and 9.5x, respectively. Company overview Gilead Sciences, Inc. is a research-based biopharmaceutical Fund Manager company that discovers, develops and commercializes innovative Royce West, CFA medicines in areas of unmet medical need. Gilead strives to 614-227-2948 transform and simplify care for people with life-threatening illnesses [email protected] around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver Analyst diseases, cancer, inflammatory and respiratory diseases, and Andrew Jasen cardiovascular conditions. 301-300-0702 [email protected] 12-Month trading performance 10.0% S&P Current share price: $72.64 7.0% 52 wk range: $71.76 - $108.13 0.0% S5HLTH Market cap: $99.9bn 1.4% P/E: 6.8x (10.0%) XBI (3.0%) Diluted shares out.: 1.3bn Last dividend (9/4/2016): $0.47 (20.0%) GILD Dividend yield: 2.4% (25.5%) Beta: 0.94 (30.0%) EV/EBITDA: 4.8x EV/Sales: 3.1x (40.0%) Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Investment thesis We are placing a BUY rating on GILD with a price target of $92.00, a 20.4% upside to the current trading price.
    [Show full text]
  • Amgen-Opinion-Jan-7-2021.Pdf
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, Plaintiffs, v. Civil Action No. 20-0561-CFC HOSPIRA, INC. and PFIZER INC. Defendants. MEMORANDUM ORDER Having considered the merits of Defendants Hospira, Inc. and Pfizer Inc.' s Motion to Stay (D.I. 19) and the briefs filed by the parties in connection with that motion, it is HEREBY ORDERED that Defendants' motion to stay is GRANTED IN PART for the following reasons: 1. Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited make and sell the biologic filgrastim under the brand name Neupogen®. Filgrastim, like many biologics, is a protein. Plaintiffs own two patents generally related to methods of purifying such proteins. These two patents are U.S. Patent Nos. 10,577,392 (the #392 patent), and 9,643,997 (the #997 patent). The #392 patent issued in March of 2020. 2. Defendants manufacture and sell a biosimilar version Neupogen® called Nivestym®. Nivestym® has been available since 2018 and is the third biosimilar version ofNeupogen® launched in the United States since Neupogen® became available almost thirty years ago. 3. Both the #392 patent and #997 patent have been asserted against the Defendants-albeit in different actions-for the manufacture ofNivestym®. The #392 patent has been asserted in this case (C.A. 20-0561 ), which was filed on April 24, 2020. The #997 patent has been asserted in the related case Amgen Inc. et al. v. Hospira, Inc. et al., No. 18-cv-1064-CFC-CJB (D. Del. 2018). That case is scheduled for a jury trial to begin on May 17, 2021.
    [Show full text]
  • In the Supreme Court of the United States   ACORDA THERAPEUTICS, INC., Petitioner
    NO. 181280 In the Supreme Court of the United States ACORDA THERAPEUTICS, INC., Petitioner, v. ROXANE LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., and TEVA PHARMACEUTICALS USA, INC., Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit BRIEF OF AMICUS CURIAE BOSTON PATENT LAW ASSOCIATION IN SUPPORT OF NEITHER PARTY SOPHIE F. WANG COUNSEL OF RECORD BRYANA T. MCGILLYCUDDY NATALIA SMYCHKOVICH CHOATE HALL & STEWART LLP TWO INTERNATIONAL PLACE BOSTON, MA 02110 (617) 248-5000 [email protected] MAY 8, 2019 COUNSEL FOR AMICUS CURIAE SUPREME COURT PRESS ʕ (888) 958-5705 ʕ BOSTON, MASSACHUSETTS i TABLE OF CONTENTS Page TABLE OF AUTHORITIES ....................................... ii INTEREST OF THE AMICUS CURIAE ................... 1 SUMMARY OF ARGUMENT .................................... 1 ARGUMENT ............................................................... 3 I. THE FEDERAL CIRCUIT’S DECISION CREATES SIGNIFICANT UNCERTAINTY CONCERNING THE SCOPE AND APPLICABILITY OF THE BLOCKING PATENT DOCTRINE. ............................................ 3 A. Clarification Is Needed as to the Definition of a “Blocking Patent.” .............. 3 B. Clarification Is Also Needed as to Whether and How the Blocking Patent Doctrine Should Be Applied to Objective Indicia of NonObviousness. ...................... 8 II. ABSENT CLARIFICATION, THE EXPANDED BLOCKING PATENT DOCTRINE HAS A CHILLING EFFECT ON INNOVATION AND INVESTMENT. .................. 11 A. Improvement Innovations Are Critical and Require Significant Investment. ....... 11 B. Objective Indicia Matter. .......................... 13 CONCLUSION .......................................................... 16 ii TABLE OF AUTHORITIES TABLE OF AUTHORITIES Page CASES Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018) ......... passim Apple v. ITC, 725 F.3d 1356 (Fed. Cir. 2013) ......................... 14 Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990) ............................................. 6 Galderma Labs., L.P.
    [Show full text]
  • Views Expressed in This Publication by Any Contributor Are Not Necessarily Those of the Publisher
    THOMSON REUTERS Expansion of the blocking-patent doctrine By Ha Kung Wong, Esq., and Michael Scerbo, Esq., Venable LLP APRIL 13, 2020 In 2005 the U.S. Court of Appeals for the Federal Circuit first Therefore, the law considers two factors to be probative of articulated the blocking-patent doctrine in Merck & Co. v. Teva whether or not an invention would have been obvious: evidence Pharmaceuticals USA Inc., 395 F.3d 1364 (Fed. Cir. 2005), or of (1) commercial success, and (2) a causal nexus between the Merck I. invention and commercial success of a product embodying it.4 The Federal Circuit said that under the doctrine courts may reduce The Federal Circuit in Merck I explained that the district court’s the weight given to evidence of commercial success where an finding of commercial success should be given only minimal earlier patent blocked market entry by others. weight because Merck had both (1) a preexisting patent covering the administration of alendronate sodium (a bisphosphonate) to The appellate court later explained in Acorda Therapeutics treat osteoporosis, and (2) exclusive marketing rights granted by Inc. v. Roxane Laboratories Inc., 903 F.3d 1310 (Fed. Cir. 2018), the Food and Drug Administration. that a patent is a blocking patent “where the practice of a later invention would infringe the earlier patent.” ”Because market entry by others was precluded on those bases, the inference of nonobviousness … from evidence of commercial The rationale behind the doctrine was that where others are legally success … is weak.”5 barred from commercializing a purportedly obvious idea due to a preexisting patent, the court may conclude that the inference of In the years after the Federal Circuit’s decision in Merck I, the court nonobviousness from evidence of commercial success is weak.
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 1 of 27 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, C.A. No. ________ Plaintiffs, v. HOSPIRA, INC. and PFIZER INC., DEMAND FOR JURY TRIAL Defendants. COMPLAINT Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited (collectively, “Plaintiffs”), by and through their undersigned attorneys, for their Complaint against Defendants Hospira, Inc. and Pfizer Inc. (collectively, “Defendants”) hereby allege as follows: THE PARTIES 1. Amgen Inc. is a corporation existing under the laws of the State of Delaware, with its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320. Amgen Inc. discovers, develops, manufactures, and sells innovative therapeutic products based on advances in molecular biology, recombinant DNA technology, and chemistry. Founded in 1980, Amgen Inc. is a pioneer in the development of biological human therapeutics. Today, Amgen Inc. is one of the largest biotechnology companies in the world, fueled in part by the success of NEUPOGEN® (filgrastim). 2. Amgen Manufacturing, Limited (“AML”) is a corporation existing under the laws of Bermuda with its principal place of business in Juncos, Puerto Rico. AML manufactures and sells biologic medicines for treating particular diseases in humans. AML is a wholly-owned subsidiary of Amgen Inc. Case 1:20-cv-00561-UNA Document 1 Filed 04/24/20 Page 2 of 27 PageID #: 2 3. On information and belief, Hospira, Inc. (“Hospira”) is a corporation existing under the laws of the State of Delaware, with its principal place of business at 275 North Field Drive, Lake Forest, Illinois 60045.
    [Show full text]
  • Percutaneous Endoscopic Gastrostomy in Pediatric Patients
    3 Percutaneous Endoscopic Gastrostomy in Pediatric Patients Omar I. Saadah Department of Pediatrics, Faculty of medicine, King Abdulaziz University Saudi Arabia 1. Introduction Adequate nutrition is important in the management of children with chronic illnesses. Patients who are unwilling or unable to eat will starve. Starvation depletes tissue stores, and ultimately leads to impaired organ function and tissue structure. Appropriate caloric intake enables growth, promotes tissue repair, and improve immune function. Access to the intestinal tract may be via a nasal tube or by the percutaneous route, with delivery to the stomach or jejunum. Nasogastric tubes are employed for short- term feeding, usually up to four weeks. In children requiring long term tube feeding, nasogastric feeding may be uncomfortable, disfiguring and often traumatic. Percutaneous access is usually by either endoscopic or radiological techniques. Percutaneous gastrostomy is basically a sutureless approximation of the stomach to the abdominal wall. The percutaneous endoscopic gastrostomy (PEG) becomes the most popular technique nowadays. The first PEG was performed in the pediatric operating room of University Hospitals of Cleveland on June 12, 1979 on a four-and-half-month-old child with inadequate oral intake. The procedure was performed under sedation and local anesthesia. The child did remarkably well. However, because the initial tube used was a 12F catheter with small mushroom head, external migration ensued after 3 weeks. The catheter was changed under direct visualization, using a small laparotomy (Gauderer, 2002). Since then the procedure has been adopted worldwide for both children and adults. Because the procedure is considered minimally invasive, rapid, and associated with low risk of complications, and short hospital stay, it has become the preferred method for delivering nutritional support in vulnerable pediatric patients.
    [Show full text]
  • ANALYSIS of AGREEMENT CONTAINING CONSENT ORDERS to AID PUBLIC COMMENT in the Matter of Pfizer Inc
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDERS TO AID PUBLIC COMMENT In the Matter of Pfizer Inc. and Hospira, Inc. File No. 151-0074 The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Orders (“Consent Agreement”) from Pfizer Inc. (“Pfizer”) and Hospira, Inc. (“Hospira”) that is designed to remedy the anticompetitive effects resulting from Pfizer’s acquisition of Hospira. Under the terms of the proposed Consent Agreement, the parties are required to divest all of Pfizer’s rights and assets related to generic acetylcysteine inhalation solution and all Hospira’s rights and assets related to clindamycin phosphate injection, voriconazole injection, and melphalan hydrochloride injection to Alvogen Group, Inc. (“Alvogen”). The proposed Consent Agreement has been placed on the public record for thirty days for receipt of comments from interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again evaluate the proposed Consent Agreement, along with the comments received, to make a final decision as to whether it should withdraw from the proposed Consent Agreement or make final the Decision and Order (“Order”). Pursuant to an Agreement and Plan of Merger executed on February 5, 2015, Pfizer proposes to acquire Hospira for approximately $16 billion (the “Proposed Acquisition”). The Commission alleges in its Complaint that the Proposed Acquisition, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, by lessening current competition in the markets for generic acetylcysteine inhalation solution and clindamycin phosphate injection and future competition in the markets for voriconazole injection and melphalan hydrochloride injection in the United States.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Managing Complications of Percutaneous Tracheostomy and Gastrostomy
    5330 Review Article on Interventional Pulmonology in the Intensive Care Unit Managing complications of percutaneous tracheostomy and gastrostomy Aline N. Zouk, Hitesh Batra Division of Pulmonary, Allergy, and Critical Care Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA Contributions: (I) Conception and design: Both authors; (II) Administrative support: Both authors; (III) Provision of study materials or patients: Both authors; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Aline N. Zouk, MD. Division of Pulmonary, Allergy, and Critical Care Medicine, The University of Alabama at Birmingham, 1900 University Blvd, THT 422, Birmingham, AL 35294, USA. Email: [email protected]. Abstract: Percutaneous tracheostomy and gastrostomy are some of the most commonly performed procedures at bedside in the intensive care unit. While they are generally considered safe, they can be associated with numerous short and long-term complications, many of which can occur long after their placement and cause significant morbidity. Performers of these procedures should possess a comprehensive understanding of procedural indications and contraindications, and know how to recognize and manage complications that may arise. In this review, we highlight complications of percutaneous tracheostomy and describe strategies for their prevention and management, with a special focus on post-tracheostomy
    [Show full text]
  • 12Th KEPAN CONGRESS ABSTRACTS
    DOI: 10.5152/ClinSciNutr.2021.080321 12th KEPAN CONGRESS ABSTRACTS Selected Abstracts for Oral Presentation NUTRITION 12th KEPAN CONGRESS ABSTRACTS SS01 Predictive Effect of a New Screening Tool for Nutritional Risk in Neonatal Intensive Care Unit Nadir Yalçın1, Hasan Tolga Çelik2, Kutay Demirkan1, Şule Yiğit2 1Hacettepe University, Faculty of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey 2Hacettepe University, Faculty of Medicine, Neonatology Unit, Department of Child Health and Diseases, Ankara, Turkey Objective: Hospitalized newborns are at increased risk of malnutrition and especially preterm infants often experience postnatal growth failure.1 It was aimed to evaluate the predictive effect of malnutrition risk on the initiation of parenteral nutrition (PN) and length of stay (LOS) while patients were admitted to neonatal intensive care unit (NICU) within 24 hours. Methods: Neonatal Nutritional Screening Tool (NNST) was prospectively applied to all infants in the NICU within 24 hours of their hospitalization. The predictive effects of NNST and birth weight on LOS and PN administration were evaluated with Poisson regres- sion analysis. The study protocol was approved by the local Ethics Committee. Results: Total of 303 patients with a mean gestational age of 35 weeks and 2 days and a mean birth weight of 2552 g were prospec- tively included in the study. According to the NNST, 27 (8.9%) of the patients had a high risk, 70 (23.1%) had a moderate risk, and 206 (68.0%) had a low nutritional risk. However, PN treatment was initiated in 118 (38.9%) of the patients. Even though, the mean LOS was 14 days for all patients, LOS was 2.7 times higher in patients with a high nutritional risk compared to patients with a low nutritional risk (p<0.001).
    [Show full text]
  • Adverse Events of Upper GI Endoscopy
    GUIDELINE Adverse events of upper GI endoscopy This is one of a series of statements discussing the use of lications rely on self-reporting, and most reported data GI endoscopy in common clinical situations. The Stan- collected only from the immediate periprocedure period, dards of Practice Committee of the American Society for thus the rate of late adverse events and mortality may be Gastrointestinal Endoscopy (ASGE) prepared this text. underestimated.8,9 Major adverse events related to diag- In preparing this document, a search of the medical liter- nostic UGI endoscopy are rare and include cardiopulmo- ature was performed by using PubMed. Additional refer- nary adverse events, infection, perforation, and bleeding. ences were obtained from the bibliographies of the identi- Adverse events of ERCP and EUS are discussed in separate fied articles and from recommendations of expert ASGE documents.10,11 consultants. When few or no data exist from well-designed prospective trials, emphasis is given to results of large series and reports from recognized experts. This document is ADVERSE EVENTS ASSOCIATED WITH based on a critical review of the available data and expert DIAGNOSTIC UGI ENDOSCOPY consensus at the time that the document was drafted. Further controlled clinical studies may be needed to clar- Cardiopulmonary adverse events ify aspects of this document. This document may be re- Most UGI procedures in the United States and Europe vised as necessary to account for changes in technology, are performed with patients under sedation (moderate or 12 new data, or other aspects of clinical practice. deep). Cardiopulmonary adverse events related to seda- This document is intended to be an educational device tion and analgesia account for as much as 60% of UGI 1-4,7 to provide information that may assist endoscopists in endoscopy adverse events.
    [Show full text]